Answers are grounded in this paper and cite their sources.
Retrospective cohort study examines surgical outcomes in adrenocortical carcinoma, suggesting implications for patient management.
INTRODUCTION: Adrenocortical cancer (ACC) is a rare endocrine malignancy with a variable prognosis. This study examines clinical outcomes of patients with ACC who underwent surgery in an endocrine surgery unit over 14 years. METHODS: Demographic, clinical, pathological and follow-up data on consecutive patients who underwent surgery for ACC or cortical tumours of uncertain malignant potential (UMP) and patients who had a clinical diagnosis of ACC were collected and descriptive analyses were conducted. RESULTS: Of 48 patients, 32 had ACC confirmed on histology, 10 had a clinical diagnosis and 6 had UMPs. Of those with a histological diagnosis, there were 12 men and 20 women with a median (range) age at first operation of 53 (16-77) years. The histologic type was oncocytic in eight (25%) patients and metastatic disease was present in six (19%) patients at time of operation. ENSAT staging was stage I in 2 (6%), stage II in 18 (56%), stage III in 5 (16%), stage IV in 6 (19%) and unknown in 1 (3%) patient. Complete resection was achieved in 16 (50%) patients. Adjuvant treatments included mitotane and external beam radiotherapy in 18 (56%) and 2 (6%) patients, respectively. Four patients (with initial surgery outside this centre) had multiple operations. The median (range) overall survival and median (range) time to persistent or recurrent disease was 33 (7-172) months and 8 (0-71) months in histology-proven ACC. CONCLUSIONS: This study provides a contemporary perspective on epidemiology and practice in the management of ACC in the UK.
No takes yet. Share an insight, caveat, or question.
Kamalakkannan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: